Overview
Binds to GIP and GLP-1 receptors on pancreatic beta cells, brain, and gut to coordinate glucose and appetite regulation.
Proposed mechanism
Dual GIP and GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, delays gastric emptying, and promotes satiety.
What the evidence supports
Human data exists but the trials are small, short-term, or not yet replicated.
Graded Human-limited
Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
Tirzepatide vs semaglutide (SURPASS-2)
· DOI:10.1056/NEJMoa2107519 · 2021
- [2]
SURMOUNT-1 weight loss
· DOI:10.1056/NEJMoa2206038 · 2022
- [3]
Tirzepatide vs semaglutide (SURPASS-2) (2021)
· · 0
- [4]
SURMOUNT-1 weight loss (2022)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.